Alaska sentinel surveillance for antimicrobial resistance in Helicobacter pylori isolates from Alaska native persons, 1999-2003

Helicobacter

Volumn 11, Issue 6, 2006, Pages 581-588

  Bruce, Michael G ^a   Bruden, Dana L ^a   McMahon, Brian J ^a,b   Hennessy, Thomas W ^a   Reasonover, Alisa ^a   Morris, Julie ^a   Hurlburt, Debby A ^a   Peters, Helen ^a   Sacco, Frank ^b   Martinez, Patrick ^b   Swenson, Michael ^c   Berg, Douglas E ^d   Parks, Debra ^a   Parkinson, Alan J ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^c Norton Sound Health Corporation   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alaska; Antibiotics; Helicobacter; Resistance; Surveillance

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; TETRACYCLINE;

ADOLESCENT; ADULT; AGAR GEL DIFFUSION; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; FEMALE; HEALTH SURVEY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INDIGENOUS PEOPLE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TIME SERIES ANALYSIS; UNITED STATES;

ADULT; AGED; ALASKA; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BIOPSY; CLARITHROMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POPULATION GROUPS; SENTINEL SURVEILLANCE; STOMACH; TETRACYCLINE;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 33750562549     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2006.00462.x     Document Type: Article

References (32)

1. Tytgat GN, Rauws EA. Campylobacter pylori and its role in peptic ulcer disease. Gastroenterol Clin North Am 1990;19:183-96.
2. Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:1233-5.
3. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995;345:1591-4.
4. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
5. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003;139:463-9.
6. Fraser AG, Moore L, Hackett M, Hollis B. Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit. Aust N Z J Medical 1999;29:512-6.
7. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000;45:68-76.
8. Pilotto A, Leandro G, Franceschi M, et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 1999;13:667-73.
9. Hoshiya S, Watanabe K, Tokunaga K, et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J Gastroenterol 2000;35:10-4.
10. Bruce M, McMahon B, Hennessy T, et al. The relationship between antimicrobial resistance and treatment outcome for H. pylori infections in Alaska Native and non-Native Persons residing in Alaska. Gastroenterol 2005;128:T944.
11. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-99. Ann Intern Med 2002;136:13-24.
12. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004;10:1088-94.
13. Parkinson AJ, Gold BD, Bulkow L, et al. High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults. Clin Diagn Lab Immunol 2000;7:885-8.
14. McMahon BJ, Bruce MG, Hennessy TW, et al. Reinfection after successful eradication of Helicobacter pylori: a 2-year prospective study in Alaska Natives. Aliment Pharmacol Ther 2006;23:1215-23.
15. Standards NCCLS. Performance standards for antimicrobial susceptibility testing and approved standard M7-A6. National Committee for Clinical Laboratory Standards 2005; Informational (Suppl.).
16. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001;161:1217-20.
17. Alarcon T, Domingo D, Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 1999;12:19-26.
18. Osato MS, Reddy R, Graham DY. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 1999;12:341-7.
19. Megraud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999;43:2747-52.
20. Taylor DE, Jiang Q, Fedorak RN. Antibiotic susceptibilities of Helicobacter pylori strains isolated in the Province of Alberta. Can J Gastroenterol 1998;12:295-8.
21. Wolle K, Nilius M, Leodolter A, Muller WA, Malfertheiner P, Konig W. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Eur J Clin Microbiol Infect Dis 1998;17:519-21.
22. Moayyedi P, Ragunathan PL, Mapstone N, Axon AT, Tompkins DS. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 1998;33:62-5.
23. Parasakthi N, Goh KL. Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia. Am J Gastroenterol 1995;90:519.
24. Vasquez A, Valdez Y, Gilman RH, et al. Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. The Gastrointestinal Physiology Working Group of Universidad Peruana Cayetano Heredia and the Johns Hopkins University. J Clin Microbiol 1996;34:1232-4.
25. Sherif M, Mohran Z, Fathy H, Rockabrand DM, Rozmajzl PJ, Frenck RW. Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt. J Clin Microbiol 2004;42:4832-4.
26. Nahar S, Mukhopadhyay AK, Khan R, et al. Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol 2004;42:4856-8.
27. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997;11:43-53.
28. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995;273:214-9.
29. Ching CK, Leung KP, Yung RW, et al. Prevalence of metronidazole-resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut 1996;38:675-8.
30. Kim JJ, Kim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 2003;8:202-6.
31. van der Hulst RW, van der Ende A, Homan A, Roorda P, Dankert J, Tytgat GN. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut 1998;42:166-9.
32. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002;123:1763-9.